FDA's Off-Label Comms Guidance Is A Reluctant Step Forward

Last month, the U.S. Food and Drug Administration published a draft guidance making recommendations for permissible proactive communications to health care providers regarding unapproved uses of approved or cleared medical products,...

Already a subscriber? Click here to view full article